U.S. Announces First New Crown Pneumonia Radiotherapy Human Trial Results With 80% Severe Accuracy

The team, led by Mohammad Khan, assistant professor of radiation oncology at Emory University School of Medicine in the United States, announced the first human trial starring in low-dose chemotherapy to treat the new coronapneumonia, with an impressive 80% efficiency in patients with severe conditions. The researchers performed a low-dose (1.5 gray) radiation on both sides of the lungs of five patients with severe new coronary pneumonia for 10 to 15 minutes, and five patients aged 64 to 94.

U.S. Announces First New Crown Pneumonia Radiotherapy Human Trial Results With 80% Severe Accuracy

Within 24 hours of radiotherapy, four patients were rapidly improved and were allowed to be discharged from the hospital. Blood tests and lung imaging tests confirmed that radiotherapy is safe and effective for treating new coronary pneumonia without side effects – no serious skin, lungs, gastrointestinal or urinary system toxicity.

One reason for the exciting trial was that the mortality rate for older patients with neo-coronary pneumonia was higher, at 8% in the 70-79 age group and 14.8% among those aged 80 and over.

Several medical institutions are conducting trials using radiotherapy to treat the new crown pneumonia.